POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Congress Urged Not to Slash Cancer Research Funding in 'Fiscal Cliff' Negotiations

Share this article:
(ChemotherapyAdvisor) – The Lung Cancer Alliance (LCA), a patient-advocacy organization, is urging Congress to “hold cancer research harmless from the fiscal cliff” during upcoming budget negotiations.

With Congress and the White House looking for ways to curtail the growth of federal spending, it is important to view cancer research budgets as “not a luxury but a necessity,” said LCA President and CEO Laurie Fenton-Ambrose.

"The incidence rate of cancer is higher now than it was 40 years ago and it is the leading cause of death in adults under the age of 75," Fenton-Ambrose said. "With the number of patients and the cost of treatment escalating, we cannot afford to short-change the agencies of government involved in cancer research and the review of new and more targeted cancer drugs now."

More funding needs to be devoted to cancers associated with high mortality rates, she argued – including lung and pancreatic cancers, which represent an estimated 33% of cancer deaths in the United States but research for which is less well-funded than other types of cancer.

She also called for a comprehensive action plan to guide public funding decisions for cancer research, and a system of benchmarks with which research outcomes can be assessed.

"This is the taxpayers' money we are investing in cancer research and treatment development and there has to be more accountability," she said.

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Lung Cancer

For Some Patients with Stage 4 Non-Small Cell Lung Cancer (NSCLC), Aggressive Treatment Improves 5-Year Survival

For Some Patients with Stage 4 Non-Small Cell ...

Aggressive treatment for low-risk stage 4 non-small cell lung cancer (NSCLC) results in a 5-year overall survival rate of 47.8%.

New Lung Cancer Immunotherapy Set to Start Clinical Trials

New Lung Cancer Immunotherapy Set to Start Clinical ...

Boehringer Ingelheim and CureVac have begun trials for a vaccine in early clinical development for the treatment of patients with lung cancer.

Chest Radiation Helps Fight Advanced Lung Cancers

Chest Radiation Helps Fight Advanced Lung Cancers

Reduces recurrence rates, improves survival when added to chemo in extensive stage small-cell lung cancer.